Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis (Financial Times)

Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis (Financial Times)

Financial Times:
Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis  —  Chief of Google’s AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships